Lyncean announces commercial operation of world's first miniature synchrotron X-ray device

Lyncean Technologies, Inc. today announced the commercial operation of a Compact Light Source (CLS), the world's first miniature synchrotron X-ray source employing state-of-the-art laser and electron beam technology.

The Lyncean CLS was purchased in December 2012 by researchers from the newly formed Center for Advanced Laser Applications in Germany, a joint project of the Ludwig Maximilians University of Munich and the Technical University Munich (TUM).

The CLS device was built and tested in Lyncean's facility in Palo Alto, Calif., and delivered to Munich in December 2014. After installation and a rapid commissioning, the CLS achieved its first X-rays on March 27 -- a date coincident with the birthday of the first Nobel laureate in physics, Wilhelm Röntgen, who discovered X-rays - -and two weeks later the CLS was fully operational.

Prof. Franz Pfeiffer, Chair of Biomedical Physics at TUM, will use the CLS for cutting-edge biomedical research that cannot be accomplished with traditional X-ray imaging devices, in areas such as breast cancer and lung disease. The CLS enables new methods of imaging, including novel phase-contrast techniques to reveal soft tissue details that previously required the X-ray technology of traditional synchrotron facilities -- billion dollar machines the size of football stadiums that take many years to build, available only at a small number of national research laboratories around the world.

Traditional synchrotrons have promoted the discovery of new materials and new methods for understanding matter at the atomic level, but for years physicists have attempted to develop a compact commercial X-ray source that would scale the technology for individual academic or industrial laboratories. Lyncean, a spin-off of SLAC National Accelerator Laboratory operated by Stanford University, is the first company to produce such a device. The Compact Light Source is the first and only commercially available miniature synchrotron. While less powerful than the largest synchrotrons, the CLS uses new technology to produce X-rays of similar quality. At one percent of the size and cost of a large synchrotron, the CLS offers researchers the convenience and efficiency of an in-house 'workstation' for X-ray science application.

Dr. Ronald Ruth, Lyncean's founder, comments that the CLS will make synchrotron X-rays locally accessible to researchers and will accelerate scientific inquiries worldwide. "Scientists have to sign up weeks or months in advance to perform experiments at large synchrotrons," Ruth said. "The CLS makes synchrotron technology readily available in the research laboratory, which dramatically increases efficiency and opens up exciting opportunities for applications only possible with a local synchrotron X-ray source."

Dr. Ruth is enthusiastic about the impact of the CLS technology on multiple fields of scientific research. "The CLS is a game-changing X-ray source that will enable significant advances in disciplines including material sciences, biomedical research, semiconductor metrology, nanotechnology and petroleum sciences," he said. "We are excited to provide research programs with a state-of-the-art tool to accelerate and expand their research capabilities."

Source: Lyncean Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine